Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay

Blood. 2019 Feb 14;133(7):763-766. doi: 10.1182/blood-2018-10-875252. Epub 2018 Dec 13.

Authors

Eli Muchtar¹, Shaji K Kumar¹, Morie A Gertz¹, Martha Grogan², Omar F AbouEzzeddine², Allan S Jaffe^{2

3}, Angela Dispenzieri¹

Affiliations

¹ Division of Hematology.
² Department of Cardiovascular Diseases, and.
³ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

PMID: 30545829
DOI: 10.1182/blood-2018-10-875252

No abstract available

Publication types

Letter

MeSH terms

Biomarkers / metabolism*
Humans
Immunoglobulin Light-chain Amyloidosis / classification
Immunoglobulin Light-chain Amyloidosis / metabolism
Immunoglobulin Light-chain Amyloidosis / pathology*
Neoplasm Staging
Risk Assessment / methods*
Troponin T / metabolism*

Substances

Biomarkers
Troponin T